A Randomized, Prospective, Double-Blind, Placebo-Controlled Trial of Terlipressin for Type 1 Hepatorenal Syndrome

Gastroenterology

Volumn 134, Issue 5, 2008, Pages 1360-1368

  Sanyal, Arun J ^a   Boyer, Thomas ^b   Garcia Tsao, Guadalupe ^c   Regenstein, Frederick ^d   Rossaro, Lorenzo ^e   Appenrodt, Beate ^f   Blei, Andres ^g   Gülberg, Veit ^h   Sigal, Samuel ⁱ   Teuber, Peter ^j  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

^c YALE UNIVERSITY   (United States)

^d TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITY OF BONN   (Germany)

^g NORTHWESTERN UNIVERSITY   (United States)

^h LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

ⁱ NewYork Presbyterian Hospital   (United States)

^j Orphan Therapeutics   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; CREATININE; PLACEBO; TERLIPRESSIN;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CYANOSIS; DEATH; DIALYSIS; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HEPATORENAL SYNDROME; HEPATORENAL SYNDROME TYPE 1; HUMAN; KIDNEY FUNCTION; LIVEDO RETICULARIS; LIVER CIRRHOSIS; LIVER FUNCTION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE; RESPIRATORY ACIDOSIS; RESPIRATORY DISTRESS; SCORING SYSTEM; SUPRAVENTRICULAR TACHYCARDIA; SURVIVAL RATE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

EID: 42949104076     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2008.02.014     Document Type: Article

References (39)

1. C. Alessandria O. Ozdogan M. Guevara MELD score and clinical type predict prognosis in hepatorenal syndrome: relevance to liver transplantation Hepatology 41 2005 1282 1289
2. A. Gines A. Escorsell P. Gines Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites Gastroenterology 105 1993 229 236
3. V. Arroyo C. Terra P. Gines Advances in the pathogenesis and treatment of type-1 and type-2 hepatorenal syndrome J Hepatol 46 2007 935 946
4. A. Rimola P. Gines V. Arroyo Urinary excretion of 6-keto-prostaglandin F1 α, thromboxane B2 and prostaglandin E2 in cirrhosis with ascites Relationship to functional renal failure (hepatorenal syndrome) J Hepatol 3 1986 111 117
5. S. Moller J. Abrahamsen H. Ring-Larsen The hepatorenal syndrome Ugeskrift for laeger 157 1995 3185 3189
6. P.Y. Martin P. Gines R.W. Schrier Nitric oxide as a mediator of hemodynamic abnormalities and sodium and water retention in cirrhosis N Engl J Med 339 1998 533 541
7. L. Dagher K. Moore The hepatorenal syndrome Gut 49 2001 729 737
8. V. Arroyo M. Guevara P. Gines Hepatorenal syndrome in cirrhosis: pathogenesis and treatment Gastroenterology 122 2002 1658 1676
9. F. Salerno A. Gerbes P. Gines Diagnosis, prevention and treatment of the hepatorenal syndrome in cirrhosis A consensus workshop of the international ascites clubGut 56 2007 1310 1318
10. V. Arroyo C. Terra P. Gines New treatments of hepatorenal syndrome Semin Liver Dis 26 2006 254 264
11. J.H. Cort I. Albrecht J. Novakova Rregional and systemic haemodynamic effect of some vasopressins: structural features of the hormone which prolong activity Eur J Clin Invest 5 1975 165 175
12. N. Ganne-Carrie A. Hadengue P. Mathurin Hepatorenal syndrome Long-term treatment with terlipressin as a bridge to liver transplantation Dig Dis Sci 41 1996 1054 1056
13. J.P. Cervoni T. Lecomte C. Cellier Terlipressin may influence the outcome of hepatorenal syndrome complicating alcoholic hepatitis Am J Gastroenterol 92 1997 2113 2114
14. J. Uriz P. Gines A. Cardenas Terlipressin plus albumin infusion: an effective and safe therapy of hepatorenal syndrome J Hepatol 33 2000 43 48
15. R. Ortega P. Gines J. Uriz Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study Hepatology 36 2002 941 948
16. I. Colle F. Durand F. Pessione Clinical course, predictive factors and prognosis in patients with cirrhosis and type 1 hepatorenal syndrome treated with Terlipressin: a retrospective analysis J Gastroenterol Hepatol 17 2002 882 888
17. R. Moreau F. Durand T. Poynard Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: a retrospective multicenter study Gastroenterology 122 2002 923 930
18. P. Solanki A. Chawla R. Garg Beneficial effects of terlipressin in hepatorenal syndrome: a prospective, randomized placebo-controlled clinical trial J Gastroenterol Hepatol 18 2003 152 156
19. A. Hadengue A. Gadano R. Moreau Beneficial effects of the 2-day administration of terlipressin in patients with cirrhosis and hepatorenal syndrome J Hepatol 29 1998 565 570
20. F. Fabrizi V. Dixit P. Martin Meta-analysis: terlipressin therapy for the hepatorenal syndrome Aliment Pharmacol Ther 24 2006 935 944
21. V. Arroyo P. Gines A.L. Gerbes Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis International Ascites Club Hepatology 23 1996 164 176
22. V. Arroyo C. Terra A. Torre Circulatory support with albumin in liver cirrhosis Gastroenterologia y hepatologia 28 2005 74 79
23. C. Duhamel J. Mauillon I. Berkelmans Hepatorenal syndrome in cirrhotic patients: terlipressine is a safe and efficient treatment; propranolol and digitalic treatments: precipitating and preventing factors? Am J Gastroenterol 95 2000 2984 2985
24. T. Restuccia R. Ortega M. Guevara Effects of treatment of hepatorenal syndrome before transplantation on posttransplantation outcome A case-control study J Hepatol 40 2004 140 146
25. F. Saner I. Kavuk H. Lang Terlipressin and gelafundin: safe therapy of hepatorenal syndrome Eur J Med Res 9 2004 78 82
26. G. Verbeke G. Molenberghs Verbeke 2000: Linear mixed models for longitudinal data 2000 Springer-Verlag New York 46 47 98–99,199–120
27. V. Arroyo Review article: hepatorenal syndrome—how to assess response to treatment and nonpharmacological therapy Aliment Pharmacol Ther 20 Suppl 3 2004 49 56
28. R. Moreau Hepatorenal syndrome in patients with cirrhosis J Gastroenterol Hepatol 17 2002 739 747
29. P. Gines Diagnosis and treatment of hepatorenal syndrome Baillieres Best Pract Res Clin Gastroenterol 14 2000 945 957
30. R.W. Schrier V. Arroyo M. Bernardi Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis Hepatology 8 1988 1151 1157
31. P. Gines G. Fernandez-Esparrach V. Arroyo Ascites and renal functional abnormalities in cirrhosis Pathogenesis and treatment Baillieres Clin Gastroenterol 11 1997 365 385
32. M. Knotek B. Rogachev R.W. Schrier Update on peripheral arterial vasodilation, ascites and hepatorenal syndrome in cirrhosis Can J Gastroenterol 14 Suppl D 2000 D112 D121
33. J.P. Mulkay H. Louis V. Donckier Long-term terlipressin administration improves renal function in cirrhotic patients with type 1 hepatorenal syndrome: a pilot study Acta Gastroenterol Belg 64 2001 15 19
34. J.M. Peron C. Bureau L. Gonzalez Treatment of hepatorenal syndrome as defined by the International Ascites Club by albumin and furosemide infusion according to the central venous pressure: a prospective pilot study Am J Gastroenterol 100 2005 2702 2707
35. J. Fernandez M. Navasa J.C. Garcia-Pagan Effect of intravenous albumin on systemic and hepatic hemodynamics and vasoactive neurohormonal systems in patients with cirrhosis and spontaneous bacterial peritonitis J Hepatol 41 2004 384 390
36. J. Fernandez J. Monteagudo X. Bargallo A randomized unblinded pilot study comparing albumin versus hydroxyethyl starch in spontaneous bacterial peritonitis Hepatology 42 2005 627 634
37. M. Guevara P. Gines G. Fernandez-Esparrach Reversibility of hepatorenal syndrome by prolonged administration of ornipressin and plasma volume expansion Hepatology 27 1998 35 41
38. V. Gulberg M. Bilzer A.L. Gerbes Long-term therapy and retreatment of hepatorenal syndrome type 1 with ornipressin and dopamine Hepatology 30 1999 870 875
39. G.N. Ioannou J. Doust D.C. Rockey Systematic review: terlipressin in acute oesophageal variceal hemorrhage Aliment Pharmacol Ther 17 2003 53 64